Harbor Capital Advisors Inc. Has $7.39 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Harbor Capital Advisors Inc. increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 60.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 64,664 shares of the company's stock after acquiring an additional 24,322 shares during the quarter. Harbor Capital Advisors Inc. owned about 0.06% of Vaxcyte worth $7,389,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Fidelis Capital Partners LLC bought a new position in shares of Vaxcyte during the 1st quarter worth about $37,000. SG Americas Securities LLC acquired a new position in Vaxcyte in the 1st quarter valued at approximately $298,000. ClariVest Asset Management LLC bought a new stake in shares of Vaxcyte in the 1st quarter worth approximately $283,000. Swiss National Bank increased its position in shares of Vaxcyte by 20.4% during the first quarter. Swiss National Bank now owns 178,000 shares of the company's stock valued at $12,159,000 after purchasing an additional 30,100 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in shares of Vaxcyte in the first quarter valued at $1,288,000. Institutional investors own 96.78% of the company's stock.

Vaxcyte Price Performance

Shares of NASDAQ PCVX traded up $0.94 during midday trading on Friday, hitting $107.29. The stock had a trading volume of 543,656 shares, compared to its average volume of 676,511. The company's 50-day simple moving average is $108.94 and its 200 day simple moving average is $86.04. The firm has a market cap of $11.97 billion, a P/E ratio of -22.93 and a beta of 1.01. Vaxcyte, Inc. has a fifty-two week low of $46.16 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same quarter last year, the business earned ($0.70) earnings per share. Equities analysts expect that Vaxcyte, Inc. will post -4.33 EPS for the current fiscal year.

Analysts Set New Price Targets

PCVX has been the topic of several analyst reports. Mizuho boosted their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a report on Tuesday, September 10th. BTIG Research increased their target price on Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Leerink Partners boosted their price target on Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a research note on Tuesday, September 3rd. Bank of America increased their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. Finally, Jefferies Financial Group boosted their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte has an average rating of "Buy" and a consensus target price of $147.50.

Insider Buying and Selling

In other Vaxcyte news, SVP Elvia Cowan sold 5,000 shares of the firm's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total transaction of $538,350.00. Following the transaction, the senior vice president now owns 12,723 shares in the company, valued at approximately $1,369,885.41. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Vaxcyte news, CFO Andrew Guggenhime sold 42,000 shares of the firm's stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,429,294.37. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Elvia Cowan sold 5,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total transaction of $538,350.00. Following the completion of the transaction, the senior vice president now directly owns 12,723 shares in the company, valued at approximately $1,369,885.41. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 92,098 shares of company stock valued at $9,937,773 over the last three months. Company insiders own 3.10% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.